Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average […]
More Stories
Neurogene Inc. (NASDAQ:NGNE) CEO Rachel Mcminn Buys 47,500 Shares
Neurogene Inc. (NASDAQ:NGNE – Get Free Report) CEO Rachel Mcminn purchased 47,500 shares of the company’s stock in a transaction...
BTCS Inc. (NASDAQ:BTCS) Director Sells $76,780.00 in Stock
BTCS Inc. (NASDAQ:BTCS – Get Free Report) Director Melanie Pump sold 22,000 shares of the firm’s stock in a transaction...
Michael S. Clifton Sells 125,000 Shares of Rigetti Computing, Inc. (NASDAQ:RGTI) Stock
Rigetti Computing, Inc. (NASDAQ:RGTI – Get Free Report) Director Michael S. Clifton sold 125,000 shares of Rigetti Computing stock in...
Autonomix Medical (NASDAQ:AMIX) Completes Underwritten Public Offering
Autonomix Medical, Inc. recently announced the conclusion of a firm commitment underwritten public offering on November 25, 2024. The offering...
News from the WHO: The first-ever global oral health conference highlights universal health coverage by 2030 https://ift.tt/CUgmzID November 25, 2024 at 07:00AM
Published on November 25, 2024 at 07:00AM View on website
Elementis (OTCMKTS:ELMTY) Hits New 52-Week High – Here’s What Happened
Elementis plc (OTCMKTS:ELMTY – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as...